ACE Inhibitors and ARBs Explained

ACE inhibitors and ARBs are two of the most prescribed cardiovascular medication classes in the world, used by tens of millions of patients for hypertension, heart failure, diabetic kidney disease, and post-myocardial infarction management. Despite their widespread use, many patients take these medications for years without understanding how they work, why their specific agent was chosen, or what side effects matter most. This guide explains both drug classes clearly — the renin-angiotensin system they target, how ACE inhibitors and ARBs differ mechanistically, what the landmark clinical trials demonstrated about their benefits, and what every patient taking either drug should know about side effects, monitoring, and safety.

The RAAS — What ACE Inhibitors and ARBs Block

The renin-angiotensin-aldosterone system (RAAS) is the primary hormonal cascade regulating blood pressure, sodium balance, and fluid volume in the body. Understanding this system explains why both ACE inhibitors and ARBs are so broadly useful across cardiovascular and renal diseases.

The cascade begins in the kidneys. When blood pressure falls, sodium delivery to the kidneys decreases, or sympathetic nervous system activity increases, the kidneys release renin — an enzyme that cleaves angiotensinogen (a large protein produced by the liver) into angiotensin I. Angiotensin I is then converted to angiotensin II by angiotensin-converting enzyme (ACE), which is found primarily in the lungs and vascular endothelium. Angiotensin II is the active effector molecule: it is a potent vasoconstrictor (raising blood pressure directly), stimulates aldosterone release from the adrenal glands (causing sodium and water retention), promotes sympathetic nervous system activity, stimulates antidiuretic hormone (ADH) secretion (reducing urinary water loss), and — over time — drives pathological remodeling of the heart and kidneys through direct fibrotic effects on cardiac and renal tissue.

ACE inhibitors block the conversion step — less angiotensin II is produced. ARBs take a complementary approach: they allow angiotensin II to be produced but block the AT1 receptor through which angiotensin II exerts its harmful vasoconstriction, aldosterone stimulation, and organ remodeling effects. Both approaches reduce blood pressure, reduce cardiac afterload (the resistance the heart must pump against), decrease aldosterone-mediated fluid retention, and over time slow the cardiac and renal remodeling driven by chronic RAAS overactivation.

ACE Inhibitors — Mechanism, Agents, and Evidence

ACE inhibitors (angiotensin-converting enzyme inhibitors) are among the most evidence-supported cardiovascular medications for broad risk reduction. The class includes lisinopril, ramipril, enalapril, captopril, perindopril, quinapril, and fosinopril. They are prodrugs (except captopril) that are converted in the liver to their active form, which then inhibits ACE throughout the body.

The breadth of clinical evidence for ACE inhibitors is remarkable. The HOPE trial (Heart Outcomes Prevention Evaluation, New England Journal of Medicine 2000) enrolled 9,297 high-cardiovascular-risk patients who did not have heart failure at baseline. Ramipril reduced the composite of cardiovascular death, myocardial infarction, and stroke by 22% over five years compared to placebo — a benefit that was particularly pronounced in diabetic patients and appeared to go beyond what could be explained by blood pressure reduction alone. The SOLVD trial demonstrated that enalapril reduced mortality by 16% and hospitalizations by 26% in patients with heart failure and reduced ejection fraction. ACE inhibitors are also proven to slow the progression of diabetic nephropathy: the Lewis trial (captopril) and subsequent studies showed that ACE inhibitor therapy reduces the rate of doubling of serum creatinine and the development of end-stage renal disease in type 1 diabetic patients with established nephropathy — independently of blood pressure effects. This renoprotective benefit extends to other forms of proteinuric kidney disease.

ARBs — Same Endpoint, Different Mechanism

ARBs (angiotensin receptor blockers) include losartan, valsartan, candesartan, irbesartan, olmesartan, telmisartan, and azilsartan. They produce cardiovascular outcomes equivalent to ACE inhibitors while avoiding the bradykinin-related side effects (cough and angioedema) by blocking the AT1 receptor rather than inhibiting ACE — and thus not affecting bradykinin metabolism.

The ONTARGET trial (New England Journal of Medicine 2008) directly compared telmisartan to ramipril in 25,620 high-cardiovascular-risk patients. Telmisartan was non-inferior to ramipril for the composite of cardiovascular death, MI, stroke, and hospitalization for heart failure over a median of 56 months. The combination of both agents was also tested — and showed no additional cardiovascular benefit while significantly increasing rates of hypotension, syncope, kidney dysfunction, and hyperkalemia. This definitively established that dual RAAS blockade (ACE inhibitor plus ARB simultaneously) provides no additional cardiovascular benefit and worsens safety — it is not recommended. The LIFE trial (losartan versus atenolol in 9,193 patients with hypertension and left ventricular hypertrophy) found that losartan reduced the composite CV endpoint by 13%, driven primarily by a 25% reduction in stroke — establishing ARBs as particularly effective for stroke prevention in hypertensive patients with LVH.

ACE Inhibitor Cough — The Most Common Reason to Switch

The most characteristic ACE inhibitor side effect is a dry, persistent, non-productive cough that affects 10 to 15% of patients in Western populations and up to 30 to 40% in Asian populations. The mechanism is direct: ACE normally degrades bradykinin and substance P in the lungs; when ACE is inhibited, these peptides accumulate in the respiratory mucosa, causing irritation and cough through neurogenic mechanisms. The cough is not an allergic reaction, it is not dangerous, and it does not predict angioedema. However, it can be sufficiently disruptive to significantly impair sleep and quality of life.

The appropriate management is to switch to an ARB, which provides equivalent cardiovascular and renal protection without affecting bradykinin levels. The cough typically resolves within one to four weeks of stopping the ACE inhibitor. Increasing the ACE inhibitor dose, changing the time of administration, or adding antitussive medications are ineffective strategies. If a patient is prescribed a new ACE inhibitor and develops cough, they should inform their prescribing physician rather than simply stopping the medication — the switch to an ARB preserves all therapeutic benefits without requiring a complete medication change in drug class.

Angioedema — Rare but Potentially Life-Threatening

ACE inhibitor-induced angioedema occurs in 0.1 to 0.5% of patients, with significantly higher rates in patients of African descent (estimated 2 to 5 times higher than in other populations). Like the cough, it is mediated by bradykinin accumulation, not by IgE-mediated allergy. Angioedema presents as sudden swelling of the lips, tongue, face, or throat — typically without urticaria (hives), which distinguishes it from allergic angioedema. Most episodes are self-limiting and involve the lips and face. However, laryngeal angioedema — swelling of the upper airway — is a medical emergency that can be rapidly fatal through asphyxiation and requires immediate epinephrine and emergency airway management.

After ACE inhibitor angioedema, the patient should never be rechallenged with any ACE inhibitor. ARBs do not cause angioedema through the bradykinin mechanism, but a small number of reports suggest occasional angioedema with ARBs in patients who previously had ACE inhibitor angioedema — possibly representing a general susceptibility to vasoactive peptide-mediated angioedema rather than a class effect. ARBs can be cautiously used after ACE inhibitor angioedema with close monitoring, particularly in patients where RAAS blockade is medically essential (HFrEF, post-MI, proteinuric CKD).

Kidney Protection — A Key Benefit Beyond Blood Pressure

One of the most important and sometimes underappreciated benefits of both ACE inhibitors and ARBs is their ability to slow the progression of chronic kidney disease (CKD) with proteinuria, independently of their blood pressure-lowering effects. In diabetic nephropathy specifically, angiotensin II causes preferential constriction of the efferent (outgoing) arteriole of the glomerulus — the filtration unit of the kidney. This efferent vasoconstriction raises intraglomerular pressure, forcing more protein through the filtration barrier (causing proteinuria) and over time damaging the delicate glomerular structure. By blocking angiotensin II production or action, ACE inhibitors and ARBs reduce efferent tone, decrease intraglomerular pressure, and reduce proteinuria — slowing the rate of nephron loss and preserving kidney function.

Current ADA (American Diabetes Association) and KDIGO (Kidney Disease Improving Global Outcomes) guidelines recommend ACE inhibitors or ARBs as first-line antihypertensive therapy in diabetic patients with microalbuminuria or macroalbuminuria, regardless of whether hypertension is also present. The renoprotective benefit applies to non-diabetic CKD with proteinuria as well, making both drug classes essential components of comprehensive CKD management.

Choosing Between an ACE Inhibitor and an ARB

For most indications, ACE inhibitors and ARBs are clinically interchangeable — they produce equivalent cardiovascular and renal outcomes in head-to-head trials. The primary reason to prefer one over the other is patient-specific: if a patient develops cough on an ACE inhibitor, switch to an ARB. If cough is anticipated as a concern (e.g., Asian patients, prior ACE inhibitor cough history, baseline lung disease making cough particularly problematic), starting directly with an ARB is reasonable. If a patient has had ACE inhibitor angioedema, use an ARB with monitoring. Some clinicians prefer ARBs as first-line in all hypertensive patients to avoid the cough issue entirely, particularly in clinical systems where managing the switch from ACE inhibitor to ARB creates administrative burden. No clear evidence favors one class over the other for cardiovascular or renal outcomes when cough is not a factor.

Monitoring — What to Expect on These Medications

Both ACE inhibitors and ARBs require monitoring of potassium and creatinine after initiation and after each dose increase, typically at one to two weeks. A creatinine rise of 10 to 30% is expected and represents the desired reduction in glomerular hyperfiltration — this is not a sign of kidney injury and does not warrant stopping the medication. A rise exceeding 30% should prompt evaluation for bilateral renal artery stenosis, severe dehydration, or concurrent NSAID use that may be amplifying the prerenal effect. Potassium above 5.5 mmol/L warrants dose reduction or medication review; potassium above 6.0 mmol/L is a serious safety threshold requiring urgent management. Both medications should be held during episodes of acute illness associated with dehydration (gastroenteritis, severe diarrhea), as reduced kidney perfusion in volume-depleted states significantly amplifies the prerenal effect of RAAS blockade.

Conclusion

ACE inhibitors and ARBs are two of the most important drug classes in cardiovascular and renal medicine, with evidence spanning heart failure, hypertension, post-myocardial infarction management, diabetic nephropathy, and broad cardiovascular risk reduction. Their shared mechanism — interrupting the RAAS at different steps — produces equivalent clinical benefits, with the primary distinction being the ACE inhibitor cough that affects 10 to 15% of patients and resolves completely when switched to an ARB. Understanding why you take one of these medications, what side effects to watch for, and why your kidney function and potassium require periodic monitoring makes these powerful medications both safer and more effective over the long term.

ACE Inhibitors and ARBs in Heart Failure

In heart failure with reduced ejection fraction (HFrEF), ACE inhibitors and ARBs address two of the key pathophysiological drivers of disease progression: elevated afterload (the resistance the weakened heart must pump against) and RAAS-driven cardiac remodeling (the progressive dilation and thinning of the ventricular wall that occurs with chronic angiotensin II exposure). By reducing angiotensin II activity, both drug classes decrease systemic vascular resistance (lowering afterload), reduce aldosterone-mediated sodium and water retention (reducing the volume overload that strains the failing heart), and over months slow the pathological cardiac remodeling that progressively worsens ventricular function.

The SOLVD treatment trial (enalapril vs. placebo in 2,569 HFrEF patients) demonstrated 16% lower all-cause mortality and 26% fewer hospitalizations for heart failure over 41 months — a robust benefit that established ACE inhibitors as a cornerstone of HFrEF pharmacotherapy. The ValHeFT trial (valsartan in HFrEF patients already on standard therapy) found that valsartan reduced the composite of mortality and morbidity in patients who could not tolerate an ACE inhibitor. Subsequently, sacubitril/valsartan (Entresto) — a combination of an ARB (valsartan) with a neprilysin inhibitor that enhances the body’s own natriuretic peptides — was shown in the PARADIGM-HF trial to be superior to enalapril alone for HFrEF mortality, and has become preferred over ACE inhibitor monotherapy in eligible patients who can tolerate it. However, ACE inhibitors and ARBs remain the foundation for patients who cannot tolerate sacubitril/valsartan or for whom it is not available.

In HFrEF patients, both ACE inhibitors and ARBs should be started at low doses and uptitrated gradually as tolerated, similar to the approach with beta blockers. The presence of some hypotension during early titration (systolic BP down to 90-100 mmHg in some patients) does not necessarily require stopping the medication — these patients often tolerate the lower blood pressure without symptoms once their body adapts. Potassium and creatinine monitoring is especially important in HFrEF patients because the combination of ACE inhibitor or ARB plus spironolactone (both of which raise potassium) and loop diuretics is standard care — polypharmacy that requires careful electrolyte management.

ACE Inhibitors and ARBs in Post-MI Management

After myocardial infarction — particularly anterior MI with significant left ventricular dysfunction — ACE inhibitors are guideline-mandatory therapy for all patients without contraindications, typically started within 24 to 48 hours of the acute event and continued long-term. The ACC/AHA guidelines recommend ACE inhibitors for all post-MI patients with LVEF 40% or below; ARBs are an equivalent alternative in patients who develop ACE inhibitor cough. The benefit in the early post-MI period comes from multiple mechanisms: reduced left ventricular afterload (allowing the damaged left ventricle to eject more efficiently), reduction in the pathological ventricular remodeling (dilation and hypertrophy) that begins within hours of MI and progresses over weeks, and anti-fibrotic effects that limit infarct expansion and reduce the development of heart failure in the months following MI. In patients with preserved left ventricular function after a small infarction, current evidence is less clear, and guidelines suggest a shorter duration of post-MI ACE inhibitor therapy in this lower-risk subgroup.

Special Populations — Diabetic Patients

ACE inhibitors and ARBs occupy a particularly important role in cardiovascular and renal care for patients with type 2 diabetes. Diabetes is the leading cause of chronic kidney disease worldwide, and diabetic nephropathy — characterized by progressive albuminuria, declining glomerular filtration rate, and eventual end-stage renal disease — affects approximately 30 to 40% of patients with diabetes over their lifetime. ACE inhibitors and ARBs reduce the rate of nephropathy progression through their intraglomerular pressure-reducing mechanism, with benefits demonstrated even in patients whose blood pressure is already at target on other antihypertensive medications.

The RENAAL trial (losartan in 1,513 patients with type 2 diabetes and nephropathy) and the IDNT trial (irbesartan in 1,715 patients with type 2 diabetic nephropathy) both showed that ARBs significantly reduced the rate of reaching the composite endpoint of doubling of creatinine, end-stage renal disease, or death compared to other antihypertensive regimens at equivalent blood pressure levels. This renoprotective effect is now a class recommendation: current ADA and KDIGO guidelines recommend ACE inhibitor or ARB therapy as the first-line choice for all patients with diabetes and chronic kidney disease associated with microalbuminuria or macroalbuminuria, regardless of whether they are hypertensive.

Heart Protection Beyond Blood Pressure — The Pleiotropic Evidence

One of the most intriguing findings from ACE inhibitor trials — particularly HOPE (ramipril) and EUROPA (perindopril) — is that the cardiovascular benefits exceed what would be predicted from blood pressure reduction alone. In HOPE, the blood pressure lowering was modest (approximately 3 mmHg systolic), yet the reduction in cardiovascular events (22%) was considerably larger than meta-analyses of BP reduction would predict for that degree of pressure lowering. This suggests that RAAS blockade provides cardiovascular protection through mechanisms beyond blood pressure: anti-inflammatory effects on the vascular endothelium, reduction of oxidative stress in arterial walls, inhibition of platelet aggregation, improvement in endothelial function and coronary vasoreactivity, and reduced progression of atherosclerotic plaque.

The EUROPA trial (perindopril in 12,218 patients with stable coronary artery disease, NEJM 2003) confirmed that perindopril reduced major cardiovascular events by 20% in patients who already had well-controlled blood pressure at baseline — further supporting the concept that ACE inhibitor benefits in established cardiovascular disease go beyond antihypertensive effects alone. This evidence base underpins the guideline recommendation for ACE inhibitors in all patients with established atherosclerotic cardiovascular disease regardless of blood pressure levels.

Related Topics on Horizon Health Guide

• Blood Pressure Medications: Types and Purpose — ACE inhibitors and ARBs in the context of all antihypertensive drug classes, including evidence from ALLHAT, ACCOMPLISH, and SPRINT
• Common Heart Medications Explained — overview of all eight cardiovascular drug classes including ACE inhibitors, ARBs, beta blockers, and diuretics
• Beta Blockers: A Simple Patient Guide — the companion drug class to ACE inhibitors in HFrEF and post-MI management with mortality evidence
• Blood Thinners: Why They Are Used — anticoagulants and antiplatelet agents that often accompany ACE inhibitors in post-MI and AF management
• Cholesterol Medications: What Adults Should Know — statins and other lipid-lowering drugs that form the rest of the evidence-based secondary prevention package alongside ACE inhibitors

Clinical References and Further Reading

• HOPE Trial — NEJM 2000: ramipril in 9,297 high-risk patients — 22% lower CV death/MI/stroke; benefits exceed blood pressure reduction alone
• ONTARGET — NEJM 2008: telmisartan non-inferior to ramipril in 25,620 patients; dual RAAS blockade offers no additional benefit
• SOLVD — NEJM 1991: enalapril in HFrEF — 16% lower mortality, 26% fewer hospitalizations